Carlos Manrique, MD
See Publications

Texas Heart Institute Positions

  • Fellow , Cardiovascular Disease Fellowship
  • Fellow, Advanced Heart Failure Fellowship

Education

  • Medical School:

    Pontifica Universidad Javeriana

  • Residency:

    Jacobi Medical Center, Albert Einstein College of Medicine

Publications

4862227 H9FABVZY 1 alternatives-to-animal-experimentation 10 date desc Manrique 1990 https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22XQI6PWN5%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Manrique%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BManrique%26lt%3B%5C%2Fstrong%26gt%3B%2C%20C.%20R.%2C%20Tiwari%2C%20N.%20and%20Plana%2C%20J.%20C.%20%282017%29.%20Cardiac%20Rhythm%20Disturbances.%20In%20%26lt%3Bi%26gt%3BAnti-Cancer%20Treatments%20and%20Cardiotoxicity%26lt%3B%5C%2Fi%26gt%3B%20%2895%26%23x2013%3B103%29.%20Elsevier.%20https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FB978-0-12-802509-3.00013-3.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22bookSection%22%2C%22title%22%3A%22Cardiac%20Rhythm%20Disturbances%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.R.%22%2C%22lastName%22%3A%22Manrique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Tiwari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.C.%22%2C%22lastName%22%3A%22Plana%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22bookTitle%22%3A%22Anti-Cancer%20Treatments%20and%20Cardiotoxicity%22%2C%22date%22%3A%222017%22%2C%22language%22%3A%22en%22%2C%22ISBN%22%3A%22978-0-12-802509-3%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FB9780128025093000133%22%2C%22collections%22%3A%5B%22H9FABVZY%22%5D%2C%22dateModified%22%3A%222018-05-21T21%3A48%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22B35W7CW4%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Manrique%20and%20Plana%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BManrique%26lt%3B%5C%2Fstrong%26gt%3B%2C%20C.%20R.%20and%20Plana%2C%20J.%20C.%20%282017%29.%20Atrial%20Fibrillation%20and%20Stroke%20in%20Cancer%20Patients.%20In%20%26lt%3Bi%26gt%3BAnti-Cancer%20Treatments%20and%20Cardiotoxicity%26lt%3B%5C%2Fi%26gt%3B%20%28131%26%23x2013%3B138%29.%20Elsevier.%20https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FB978-0-12-802509-3.00019-4.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22bookSection%22%2C%22title%22%3A%22Atrial%20Fibrillation%20and%20Stroke%20in%20Cancer%20Patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.R.%22%2C%22lastName%22%3A%22Manrique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.C.%22%2C%22lastName%22%3A%22Plana%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22bookTitle%22%3A%22Anti-Cancer%20Treatments%20and%20Cardiotoxicity%22%2C%22date%22%3A%222017%22%2C%22language%22%3A%22en%22%2C%22ISBN%22%3A%22978-0-12-802509-3%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FB9780128025093000194%22%2C%22collections%22%3A%5B%22H9FABVZY%22%5D%2C%22dateModified%22%3A%222018-05-21T21%3A48%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22KK4WCNV3%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Manrique%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BManrique%26lt%3B%5C%2Fstrong%26gt%3B%2C%20C.%20R.%2C%20Park%2C%20M.%2C%20Tiwari%2C%20N.%20et%20al.%20%282017%29.%20Diagnostic%20strategies%20for%20early%20recognition%20of%20cancer%20therapeutics-related%20cardiac%20dysfunction.%20%26lt%3Bi%26gt%3BClin%20Med%20Insights%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B11%26lt%3B%5C%2Fi%26gt%3B%2C%201179546817697983.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1179546817697983%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1179546817697983%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnostic%20strategies%20for%20early%20recognition%20of%20cancer%20therapeutics-related%20cardiac%20dysfunction%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%20R.%22%2C%22lastName%22%3A%22Manrique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nidhish%22%2C%22lastName%22%3A%22Tiwari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Carlos%22%2C%22lastName%22%3A%22Plana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%20J.%22%2C%22lastName%22%3A%22Garcia%22%7D%5D%2C%22abstractNote%22%3A%22Cardiovascular%20toxicity%20in%20the%20form%20of%20cardiac%20dysfunction%20continues%20to%20be%20an%20obstacle%20for%20patients%20with%20cancer.%20Survival%20and%20quality%20of%20life%20of%20cancer%20survivors%20are%20frequently%20affected%20by%20increased%20incidence%20of%20cardiovascular%20disease.%20The%20involvement%20of%20the%20cardiovascular%20system%20by%20primary%20or%20secondary%20malignancies%2C%20as%20well%20as%20its%20dysfunction%20secondary%20to%20the%20administration%20of%20antineoplastics%2C%20has%20led%20to%20the%20development%20of%20a%20new%20discipline%20called%20Cardio-Oncology%2C%20an%20exciting%20cardiology%20subspecialty%20with%20more%20questions%20than%20answers%20and%20as%20a%20result%20an%20enormous%20opportunity%20for%20research%20in%20the%20field.%20Multidisciplinary%20efforts%20have%20been%20focused%20on%20the%20prevention%2C%20diagnosis%2C%20and%20treatment%20of%20cancer%20therapeutics-related%20cardiovascular%20dysfunction%20%28CTRCD%29.%20This%20review%20article%20will%20focus%20on%20the%20early%20diagnosis%20of%20left%20ventricular%20dysfunction%20associated%20with%20chemotherapy.%20Currently%2C%20the%20identification%20of%20cardiac%20toxicity%20associated%20with%20cancer%20treatment%20is%20the%20cornerstone%20for%20critical%20decisions%20regarding%20anticancer%20therapy%20and%20cardioprotective%20strategies.%20Its%20early%20detection%2C%20especially%20in%20subclinical%20phases%2C%20allows%20immediate%20intervention%20to%20prevent%20further%20impairment%20of%20the%20myocardium%20and%20other%20cardiovascular%20structures.%20The%20most%20significant%20published%20studies%20were%20selected%20for%20this%20revision%2C%20providing%20an%20updated%20document%20for%20the%20health%20professionals%20involved%20in%20the%20care%20of%20patients%20with%20cancer.%20We%20examined%20the%20current%20evidence%20and%20recommendations%20for%20biochemical%20and%20noninvasive%20diagnostic%20techniques%2C%20including%20their%20specific%20role%20for%20identification%20of%20CTRCD.%20Traditional%20and%20advanced%20imaging%20modalities%2C%20used%20alone%20or%20in%20combination%20with%20cardiovascular%20biomarkers%2C%20are%20essential%20for%20the%20recognition%20of%20cardiotoxicity%20during%20cancer%20therapy.%20Evolving%20basic%20and%20clinical%20research%20are%20focused%20on%20the%20development%20of%20more%20sensitive%20and%20specific%20diagnostic%20tools%20and%20for%20the%20recognition%20of%20cardiac%20toxicity.%22%2C%22date%22%3A%222017%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F1179546817697983%22%2C%22ISSN%22%3A%221179-5468%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22M32R8FP2%22%2C%22H9FABVZY%22%5D%2C%22dateModified%22%3A%222018-05-07T17%3A50%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22P6NV86E6%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Yu%20et%20al.%22%2C%22parsedDate%22%3A%222016-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BYu%2C%20A.%20F.%2C%20%26lt%3Bstrong%26gt%3BManrique%26lt%3B%5C%2Fstrong%26gt%3B%2C%20C.%2C%20Pun%2C%20S.%20et%20al.%20%282016%29.%20Cardiac%20safety%20of%20paclitaxel%20plus%20trastuzumab%20and%20pertuzumab%20in%20patients%20with%20HER2-positive%20metastatic%20breast%20cancer.%20%26lt%3Bi%26gt%3BOncologist%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B21%26lt%3B%5C%2Fi%26gt%3B%2C%20418%26%23x2013%3B424.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1634%5C%2Ftheoncologist.2015-0321%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1634%5C%2Ftheoncologist.2015-0321%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cardiac%20safety%20of%20paclitaxel%20plus%20trastuzumab%20and%20pertuzumab%20in%20patients%20with%20HER2-positive%20metastatic%20breast%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%20F.%22%2C%22lastName%22%3A%22Yu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Manrique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shawn%22%2C%22lastName%22%3A%22Pun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20E.%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elton%22%2C%22lastName%22%3A%22Mara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Fleisher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sujata%22%2C%22lastName%22%3A%22Patil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lee%20W.%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20M.%22%2C%22lastName%22%3A%22Steingart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clifford%20A.%22%2C%22lastName%22%3A%22Hudis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chau%20T.%22%2C%22lastName%22%3A%22Dang%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Myocardial%20strain%20imaging%20and%20blood%20biomarkers%20have%20been%20proposed%20as%20adjuncts%20to%20left%20ventricular%20ejection%20fraction%20%28LVEF%29%20monitoring%20for%20the%20early%20detection%20of%20cardiotoxicity%20during%20cancer%20therapy.%20We%20report%20the%20results%20of%20a%20preplanned%20cardiac%20safety%20analysis%20of%20global%20longitudinal%20strain%20%28GLS%29%2C%20and%20troponin-I%20%28TnI%29%20and%20brain%20natriuretic%20peptide%20%28BNP%29%20levels%20in%20the%20phase%20II%20study%20of%20paclitaxel%2C%20trastuzumab%2C%20and%20pertuzumab%20%28THP%29%20for%20metastatic%20HER2-positive%20breast%20cancer.%5CnPATIENTS%20AND%20METHODS%3A%20Patients%20with%200-1%20lines%20of%20prior%20therapy%20were%20treated%20with%20weekly%20paclitaxel%20%2880%20mg%5C%2Fm%282%29%29%20plus%20trastuzumab%20%288%20mg%5C%2Fkg%20loading%20dose%20followed%20by%206%20mg%5C%2Fkg%29%20and%20pertuzumab%20%28840%20mg%20loading%20dose%20followed%20by%20420%20mg%29%20every%203%20weeks.%20Exploratory%20endpoints%20were%20GLS%20measured%20with%20speckle-tracking%20echocardiography%20every%203%20months%20and%20TnI%20and%20BNP%20levels%20measured%20every%206%20weeks%20%28immediately%20pre-%20and%20postchemotherapy%20infusion%29%20at%206%20time%20points.%5CnRESULTS%3A%20Sixty-seven%20of%2069%20enrolled%20patients%20were%20treated%20with%20THP%3A%2019%20%2828%25%29%20had%20hypertension%2C%208%20%2812%25%29%20had%20diabetes%2C%2011%20%2816%25%29%20had%20hyperlipidemia%2C%20and%2026%20%2838%25%29%20had%20smoking%20history.%20After%20a%20median%20follow-up%20of%2021%20months%20%28range%3A%203-38%20months%29%2C%20no%20patients%20developed%20symptomatic%20heart%20failure.%20Two%20patients%20%283.0%25%29%20experienced%20asymptomatic%20LVEF%20decline%20%28grade%202%29.%20The%20mean%20GLS%20%28%5Cu00b1SD%29%20was%2019%25%20%5Cu00b1%202%25%20%28baseline%29%2C%2019%25%20%5Cu00b1%202%25%20%28month%206%29%2C%20and%2019%25%20%5Cu00b1%203%25%20%28month%2012%29.%20Detectable%20TnI%20%28%26gt%3B0.06%20ng%5C%2FmL%29%20and%20elevated%20BNP%20%28%26gt%3B100%20pg%5C%2FmL%29%20levels%20were%20observed%20in%203%20%284.3%25%29%20and%202%20%283.0%25%29%20patients%2C%20respectively%2C%20but%20were%20not%20associated%20with%20LVEF%20decline.%5CnCONCLUSION%3A%20The%20absence%20of%20any%20significant%20changes%20in%20GLS%20and%20cardiac%20biomarkers%20%28TnI%20and%20BNP%29%20further%20support%20the%20cardiac%20safety%20of%20THP%20in%20patients%20with%20metastatic%20HER2-positive%20breast%20cancer.%5CnIMPLICATIONS%20FOR%20PRACTICE%3A%20Dual%20anti-HER2%20therapy%20with%20trastuzumab%20and%20pertuzumab%20in%20combination%20with%20taxane-based%20chemotherapy%20improves%20overall%20survival%20in%20patients%20with%20metastatic%20HER2-positive%20breast%20cancer.%20There%20is%20a%20critical%20need%20to%20investigate%20the%20potential%20cardiotoxicity%20of%20dual%20anti-HER2%20blockade%2C%20given%20the%20importance%20of%20HER2%20signaling%20in%20cardiac%20homeostasis%20and%20stress%20response.%20Global%20longitudinal%20strain%20and%20cardiac%20biomarkers%20have%20been%20proposed%20as%20adjuncts%20to%20left%20ventricular%20ejection%20fraction%20for%20the%20early%20detection%20of%20cardiotoxicity.%20In%20this%20phase%20II%20study%20of%20combination%20trastuzumab%20and%20pertuzumab%20with%20paclitaxel%2C%20no%20clinically%20significant%20change%20was%20observed%20in%20global%20longitudinal%20strain%20or%20cardiac%20biomarkers.%20These%20results%20further%20support%20the%20cardiac%20safety%20of%20dual%20anti-HER2%20blockade%20previously%20reported%20in%20the%20CLEOPATRA%20study.%20The%20findings%20in%20the%20current%20study%20also%20call%20into%20question%20the%20role%20of%20intensive%20cardiac%20monitoring%20among%20patients%20treated%20with%20anti-HER2%20therapy%20in%20the%20absence%20of%20anthracyclines.%20Less%20frequent%20cardiac%20assessments%20could%20lead%20to%20a%20reduction%20in%20unnecessary%20treatment%20interruption%20and%20is%20an%20important%20consideration%20given%20the%20rise%20in%20medical%20expenditures%2C%20but%20this%20requires%20further%20investigation.%22%2C%22date%22%3A%22Apr%202016%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1634%5C%2Ftheoncologist.2015-0321%22%2C%22ISSN%22%3A%221549-490X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22H9FABVZY%22%5D%2C%22dateModified%22%3A%222018-05-21T15%3A16%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22PM4E4YBQ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wever-Pinzon%20et%20al.%22%2C%22parsedDate%22%3A%222014-05-20%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWever-Pinzon%2C%20O.%2C%20Romero%2C%20J.%2C%20Kelesidis%2C%20I.%20et%20al.%20%282014%29.%20Coronary%20computed%20tomography%20angiography%20for%20the%20detection%20of%20cardiac%20allograft%20vasculopathy%3A%20a%20meta-analysis%20of%20prospective%20trials.%20%26lt%3Bi%26gt%3BJ%20Am%20Coll%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B63%26lt%3B%5C%2Fi%26gt%3B%2C%201992%26%23x2013%3B2004.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2014.01.071%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2014.01.071%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Coronary%20computed%20tomography%20angiography%20for%20the%20detection%20of%20cardiac%20allograft%20vasculopathy%3A%20a%20meta-analysis%20of%20prospective%20trials%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Omar%22%2C%22lastName%22%3A%22Wever-Pinzon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Romero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iosif%22%2C%22lastName%22%3A%22Kelesidis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Wever-Pinzon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Manrique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deborah%22%2C%22lastName%22%3A%22Budge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stavros%20G.%22%2C%22lastName%22%3A%22Drakos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ileana%20L.%22%2C%22lastName%22%3A%22Pi%5Cu00f1a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdallah%20G.%22%2C%22lastName%22%3A%22Kfoury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%20J.%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josef%22%2C%22lastName%22%3A%22Stehlik%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20This%20study%20aimed%20to%20evaluate%20the%20diagnostic%20accuracy%20of%20coronary%20computed%20tomography%20angiography%20%28CCTA%29%20for%20detecting%20cardiac%20allograft%20vasculopathy%20%28CAV%29%20in%20comparison%20with%20conventional%20coronary%20angiography%20%28CCAG%29%20alone%20or%20with%20intravascular%20ultrasound%20%28IVUS%29.%5CnBACKGROUND%3A%20CAV%20limits%20long-term%20survival%20after%20heart%20transplantation%2C%20and%20screening%20for%20CAV%20is%20performed%20on%20annual%20basis.%20CCTA%20is%20currently%20not%20recommended%20for%20CAV%20screening%20due%20to%20the%20limited%20accuracy%20reported%20by%20early%20studies.%20Technological%20advances%2C%20however%2C%20might%20have%20resulted%20in%20improved%20test%20performance%20and%20might%20justify%20re-evaluation%20of%20this%20recommendation.%5CnMETHODS%3A%20A%20systematic%20review%20of%20Medline%2C%20Cochrane%2C%20and%20Embase%20for%20all%20prospective%20trials%20assessing%20CAV%20using%20CCTA%20was%20performed%20using%20a%20standard%20approach%20for%20meta-analysis%20for%20diagnostic%20test%20and%20a%20bivariate%20analysis.%5CnRESULTS%3A%20Thirteen%20studies%20evaluating%20615%20patients%20%28mean%20age%2052%20years%2C%2083%25%20male%29%20and%209%2C481%20segments%20fulfilled%20inclusion%20criteria.%20Patient-based%20analyses%20comparing%20CCTA%20versus%20CCAG%20for%20the%20detection%20of%20any%20CAV%20%28%26gt%3B%20luminal%20irregularities%29%20and%20significant%20CAV%20%28stenosis%5Cu00a0%5Cu226550%25%29%2C%20showed%20mean%20weighted%20sensitivities%20of%2097%25%20and%2094%25%2C%20specificities%20of%2081%25%20and%5Cu00a092%25%2C%20a%20negative%20predictive%20value%20%28NPV%29%20of%2097%25%20and%2099%25%2C%20a%20positive%20predictive%20value%20%28PPV%29%20of%2078%25%20and%2067%25%2C%20and%5Cu00a0diagnostic%20accuracies%20of%2088%25%20and%2094%25%2C%20respectively.%20There%20was%20a%20strong%20trend%20toward%20improved%20sensitivity%20%2897%25%5Cu00a0vs.%5Cu00a091%25%2C%20p%5Cu00a0%3D%200.06%29%20and%20NPV%20%2899%25%20vs.%2097%25%2C%20p%5Cu00a0%3D%200.06%29%20to%20detect%20significant%20CAV%20with%2064-slice%20compared%20with%2016-slice%20CCTA.%20A%20patient-based%20analysis%20of%2064-slice%20CCTA%20versus%20IVUS%20showed%20a%20mean%20weighted%20sensitivity%20and%20specificity%20of%2081%25%20and%2075%25%20to%20detect%20CAV%20%28intimal%20thickening%20%26gt%3B0.5%20mm%29%2C%20whereas%20the%20PPV%20and%20NPV%20were%2093%25%20and%2050%25%2C%20respectively.%5CnCONCLUSIONS%3A%20CCTA%20using%20currently%20available%20technology%20is%20a%20reliable%20noninvasive%20imaging%20alternative%20to%20coronary%20angiography%20with%5Cu00a0an%20excellent%20sensitivity%2C%20specificity%2C%20and%20NPV%20for%20the%20detection%20of%20CAV.%22%2C%22date%22%3A%22May%2020%2C%202014%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jacc.2014.01.071%22%2C%22ISSN%22%3A%221558-3597%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22H9FABVZY%22%5D%2C%22dateModified%22%3A%222018-05-21T15%3A14%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22M7YI5VVU%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Steingart%20et%20al.%22%2C%22parsedDate%22%3A%222013-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSteingart%2C%20R.%20M.%2C%20Yadav%2C%20N.%2C%20%26lt%3Bstrong%26gt%3BManrique%26lt%3B%5C%2Fstrong%26gt%3B%2C%20C.%20et%20al.%20%282013%29.%20Cancer%20survivorship%3A%20cardiotoxic%20therapy%20in%20the%20adult%20cancer%20patient%3B%20cardiac%20outcomes%20with%20recommendations%20for%20patient%20management.%20%26lt%3Bi%26gt%3BSemin%20Oncol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B40%26lt%3B%5C%2Fi%26gt%3B%2C%20690%26%23x2013%3B708.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1053%5C%2Fj.seminoncol.2013.09.010%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1053%5C%2Fj.seminoncol.2013.09.010%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cancer%20survivorship%3A%20cardiotoxic%20therapy%20in%20the%20adult%20cancer%20patient%3B%20cardiac%20outcomes%20with%20recommendations%20for%20patient%20management%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20M.%22%2C%22lastName%22%3A%22Steingart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nandini%22%2C%22lastName%22%3A%22Yadav%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Manrique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20R.%22%2C%22lastName%22%3A%22Carver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Liu%22%7D%5D%2C%22abstractNote%22%3A%22Many%20types%20of%20cancer%20are%20now%20curable%20or%2C%20if%20not%20cured%2C%20becoming%20a%20chronic%20illness.%20In%202012%2C%20it%20was%20estimated%20that%20there%20were%20more%20than%2013%2C500%2C000%20cancer%20survivors%20in%20the%20United%20States.%20Late%20outcomes%20of%20these%20survivors%20are%20increasingly%20related%20to%20cardiovascular%20disease%2C%20either%20as%20a%20consequence%20of%20the%20direct%20effects%20of%20cancer%20therapy%20or%20its%20adverse%20effects%20on%20traditional%20cardiac%20risk%20factors%20%28eg%2C%20obesity%2C%20hypertension%2C%20dyslipidemia%2C%20and%20diabetes%20mellitus%29.%20This%20article%20describes%20the%20therapies%20that%20have%20led%20to%20advances%20in%20cancer%20survival%20and%20the%20acute%20and%20chronic%20cardiovascular%20toxicities%20associated%20with%20these%20therapies.%20Recommendations%20are%20made%20for%20the%20surveillance%20and%20management%20of%20cancer%20survivors.%20Published%20guidelines%20on%20the%20subject%20of%20cardio-oncology%20are%20reviewed%20in%20light%20of%20clinical%20experience%20caring%20for%20these%20patients.%20To%20supplement%20this%20cancer-related%20knowledge%20base%2C%20appropriateness%20criteria%20and%20guidelines%20for%20cardiac%20care%20in%20the%20general%20population%20were%20extrapolated%20to%20cancer%20survivors.%20The%20result%20is%20a%20series%20of%20recommendations%20for%20surveillance%20and%20management%20of%20cardiovascular%20disease%20in%20cancer%20survivors.%22%2C%22date%22%3A%22Dec%202013%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1053%5C%2Fj.seminoncol.2013.09.010%22%2C%22ISSN%22%3A%221532-8708%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22H9FABVZY%22%5D%2C%22dateModified%22%3A%222018-05-21T15%3A14%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22YK545EWQ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Romero%20et%20al.%22%2C%22parsedDate%22%3A%222013%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRomero%2C%20J.%2C%20Mejia-Lopez%2C%20E.%2C%20%26lt%3Bstrong%26gt%3BManrique%26lt%3B%5C%2Fstrong%26gt%3B%2C%20C.%20et%20al.%20%282013%29.%20Arrhythmogenic%20right%20ventricular%20cardiomyopathy%20%28ARVC%5C%2FD%29%3A%20a%20systematic%20literature%20review.%20%26lt%3Bi%26gt%3BClin%20Med%20Insights%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B7%26lt%3B%5C%2Fi%26gt%3B%2C%2097%26%23x2013%3B114.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.4137%5C%2FCMC.S10940%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.4137%5C%2FCMC.S10940%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Arrhythmogenic%20right%20ventricular%20cardiomyopathy%20%28ARVC%5C%2FD%29%3A%20a%20systematic%20literature%20review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Romero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliany%22%2C%22lastName%22%3A%22Mejia-Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Manrique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Lucariello%22%7D%5D%2C%22abstractNote%22%3A%22Arrhythmogenic%20right%20ventricular%20cardiomyopathy%5C%2Fdysplasia%20%28ARVC%5C%2FD%29%20is%20a%20genetic%20form%20of%20cardiomyopathy%20%28CM%29%20usually%20transmitted%20with%20an%20autosomal%20dominant%20pattern.%20It%20primary%20affects%20the%20right%20ventricle%20%28RV%29%2C%20but%20may%20involve%20the%20left%20ventricle%20%28LV%29%20and%20culminate%20in%20biventricular%20heart%20failure%20%28HF%29%2C%20life%20threatening%20ventricular%20arrhythmias%20and%20sudden%20cardiac%20death%20%28SCD%29.%20It%20accounts%20for%2011%25-22%25%20of%20cases%20of%20SCD%20in%20the%20young%20athlete%20population.%20Pathologically%20is%20characterized%20by%20myocardial%20atrophy%2C%20fibrofatty%20replacement%20and%20chamber%20dilation.%20Diagnosis%20is%20often%20difficult%20due%20to%20the%20nonspecific%20nature%20of%20the%20disease%20and%20the%20broad%20spectrum%20of%20phenotypic%20variations.%20Therefore%20consensus%20diagnostic%20criteria%20have%20been%20developed%20and%20combined%20electrocardiography%2C%20echocardiography%2C%20cardiac%20magnetic%20resonance%20imaging%20%28CMRI%29%20and%20myocardial%20biopsy.%20Early%20detection%2C%20family%20screening%20and%20risk%20stratification%20are%20the%20cornerstones%20in%20the%20diagnostic%20evaluation.%20Implantable%20cardioverter-defibrillator%20%28ICD%29%20implantation%2C%20ablative%20procedures%20and%20heart%20transplantation%20are%20currently%20the%20main%20therapeutic%20options.%22%2C%22date%22%3A%222013%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.4137%5C%2FCMC.S10940%22%2C%22ISSN%22%3A%221179-5468%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22H9FABVZY%22%5D%2C%22dateModified%22%3A%222018-05-21T15%3A15%3A26Z%22%7D%7D%5D%7D
Manrique, C. R., Tiwari, N. and Plana, J. C. (2017). Cardiac Rhythm Disturbances. In Anti-Cancer Treatments and Cardiotoxicity (95–103). Elsevier. https://doi.org/10.1016/B978-0-12-802509-3.00013-3.
Manrique, C. R. and Plana, J. C. (2017). Atrial Fibrillation and Stroke in Cancer Patients. In Anti-Cancer Treatments and Cardiotoxicity (131–138). Elsevier. https://doi.org/10.1016/B978-0-12-802509-3.00019-4.
Manrique, C. R., Park, M., Tiwari, N. et al. (2017). Diagnostic strategies for early recognition of cancer therapeutics-related cardiac dysfunction. Clin Med Insights Cardiol 11, 1179546817697983. https://doi.org/10.1177/1179546817697983.
Yu, A. F., Manrique, C., Pun, S. et al. (2016). Cardiac safety of paclitaxel plus trastuzumab and pertuzumab in patients with HER2-positive metastatic breast cancer. Oncologist 21, 418–424. https://doi.org/10.1634/theoncologist.2015-0321.
Wever-Pinzon, O., Romero, J., Kelesidis, I. et al. (2014). Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials. J Am Coll Cardiol 63, 1992–2004. https://doi.org/10.1016/j.jacc.2014.01.071.
Steingart, R. M., Yadav, N., Manrique, C. et al. (2013). Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. Semin Oncol 40, 690–708. https://doi.org/10.1053/j.seminoncol.2013.09.010.
Romero, J., Mejia-Lopez, E., Manrique, C. et al. (2013). Arrhythmogenic right ventricular cardiomyopathy (ARVC/D): a systematic literature review. Clin Med Insights Cardiol 7, 97–114. https://doi.org/10.4137/CMC.S10940.